This is a renewal application for the Indiana Adult AIDS Clinical Trials Unit. It is a combined application for the Indiana University ACTU and its subunit at Methodist Hospital of Indianapolis. The primary objective of the Indiana ACTU is to assist the AIDS Clinical Trials Group (ACTG) to develop and implement high quality clinical trials in AIDS and to provide new ideas to advance knowledge of the pathogenesis of the disease and identify effective treatment.
Specific Aims Of Indiana ACTU 1. Improve services to women and minorities. 2. Increase patient base to implement ACTG agenda. 3. Expand relevant virology and immunology support. 4. Promote ACTG scientific and administrative agenda. These goals will be achieved by creation of a unit at our Wishard Memorial Hospital (county hospital), which serves a disproportionate number of women (17%) and African-Americans (45%) with HIV-infection, expansion of our community outreach program, and addition of investigators who will contribute to the ACTG scientific and administrative agenda, provide cultural diversity necessary to recruit underrepresented patients, and provide gynecologic expertise needed to implement the Women's Health committee agenda. Collaboration between Indiana investigators and scientists in industry and academic institutions will bring new ideas to the ACTG in areas of high priority, including immunopathogenesis and immune based therapy, prevention and treatment of resistant candidiasis, pathogenesis of HIV wasting, treatment of human papilloma virus infection, and use of PCR as an early marker for PCP and histoplasmosis. Work proposed in this application will be implemented through an integrated HIV care and research program at the Indiana University Medical Center and Methodist Hospital directed by the principal investigator with the assistance of experienced and new co-investigators and skilled ACTU personnel. Strong community support characterizes the environment for HIV investigation at the Indiana University ACTU.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025859-12
Application #
2633462
Study Section
Special Emphasis Panel (SRC (82))
Project Start
1987-09-30
Project End
1999-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 181 publications